In the LARISSA project, six consortium partners work with CEPI to develop and validate a novel vaccine against Rift Valley Fever. It is the first vaccine that potentially provides full protection with a single dose and has an optimal safety profile. 

Subscribe to Our Newsletter

CONTACT >

E: info@bunyavax.com

© 2019 by BunyaVax BV.

Developing a human Rift Valley fever vaccine

Find out more about the consortium and CEPI

Read here how LARISSA takes action to prepare against future Rift Valley Fever outbreaks

Everything you need to know about Rift Valley Fever and the development of a vaccine

Reach out

Learn more about LARISSA from the project coordinator